首页/数据集/Inhibition of PARP14 restores response to α-PD1 immune checkpoint inhibition in tumours with resistance driven by IFNγ. IFNG Study.

Inhibition of PARP14 restores response to α-PD1 immune checkpoint inhibition in tumours with resistance driven by IFNγ. IFNG Study.

ChEBI2023-08-22 更新2026-07-12 收录

化疗耐药机制

免疫检查点抑制剂联合治疗

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-MTAB-12196 数据链接链接失效反馈

官方服务：

资源简介：

Inhibition of PARP14 restores response to α-PD1 immune checkpoint inhibition in tumours with resistance driven by IFNγ. IFNG Study.

应用场景：

创建时间：

2023-08-22

头颈部鳞状细胞癌基因

化疗耐药机制

In order to investigate the mechanisms underlying response and resistance towards treatment in HNSCC, we used low passage in vitro HNSCC cultures from two patients, namely SJG26 and SJG17. Both cultur

NIAID Data Ecosystem70

MRTF/SRF link the cytoskeleton and hedgehog pathway in drug-resistant basal cell carcinomas

化疗耐药机制

Hedgehog信号通路

We use multi-dimensional genomic analysis using mouse resistant BCCs to identify a non-canonical hedgehog activation pathway driven by the transcription factor, serum response factor (SRF). RNA and wh

NIAID Data Ecosystem50

DataSheet2_Exogenous proline enhances susceptibility of NSCLC to cisplatin via metabolic reprogramming and PLK1-mediated cell cycle arrest.xlsx

化疗耐药机制

代谢重编程

The occurrence of cisplatin resistance is still the main factor limiting the therapeutic effect of non-small cell lung cancer (NSCLC). It is urgent to elucidate the resistance mechanism and develop no

NIAID Data Ecosystem40

Integrative Analyses of Gene Expression and DNA Methylation Profiles in a Breast Cancer Cell Line Model of Tamoxifen-Resistance Indicate a Crucial Role of Cells with Stem-like Properties. Homo sapiens

化疗耐药机制

表观遗传调控

Purpose: Development of resistance to tamoxifen is an important clinical issue in the treatment of patients with breast cancer. Tamoxifen resistance may be the result of the acquisition of epigenetic

NIAID Data Ecosystem50

Loss of IFN-g signaling in tumor cells associates with primary resistance to anti-CTLA-4 therapy

化疗耐药机制

IFN-γ信号通路

"Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-?,

NIAID Data Ecosystem40

Inhibition of PARP14 restores response to α-PD1 immune checkpoint inhibition in tumours with resistance driven by IFNγ. IFNG Study.

资源简介：

相关数据集